260
Participants
Start Date
August 8, 2023
Primary Completion Date
December 31, 2025
Study Completion Date
March 21, 2028
BL-B01D1
BL-B01D1 will be administered either on a Day 1 or Day 1 Day 8 dosing regimen
RECRUITING
Memorial Sloan Kettering Cancer Center Head Neck Services, New York
RECRUITING
Georgetown University Medical Center, Washington D.C.
RECRUITING
Virginia Cancer Specialists, Fairfax
RECRUITING
PRISMA Health/ITOR, Greenville
RECRUITING
Sara Cannon Research Institute Lake Nona, Orlando
RECRUITING
Sylvester Comprehensive Cancer Center, Miami
RECRUITING
Hematology - Oncology Associates of the Treasure Coast, Port Saint Lucie
RECRUITING
Sarah Cannon - Tennessee Oncology, Nashville
RECRUITING
Norton Cancer Institute, Louisville
RECRUITING
University of Iowa Hospital and Clinics, Iowa City
RECRUITING
Northwestern University Feinberg School of Medicine, Chicago
RECRUITING
Oncology Consultants, P.A., Houston
RECRUITING
University of Texas M.D. Anderson Cancer Center, Houston
RECRUITING
University of Colorado Cancer Center, Aurora
RECRUITING
Beverly Hills Cancer Center, Beverly Hills
RECRUITING
UCLA Santa Monica, Santa Monica
RECRUITING
City of Hope Cancer Center, Duarte
RECRUITING
University of California Irvine Medical Center, Orange
RECRUITING
University of Washington Fred Hutchinson, Seattle
RECRUITING
Yale University, Yale Cancer Center, New Haven
RECRUITING
Massachusetts General Hospital, Boston
RECRUITING
Dana-Farber Cancer Institute, Boston
SystImmune Inc.
INDUSTRY